The results of three studies could usher in a new era of fixed-dose oral thromboprophylaxis. Prophylactic anticoagulation is recommended practice following total knee and hip arthroplasty. Commonly ...

Oral edoxaban showed superior results to subcutaneous enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty, according to findings published in Thrombosis Journal. “In ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients who received either aspirin or enoxaparin for ...

Low-molecular-weight heparins such as enoxaparin have shown benefit in MI and unstable angina and have been more effective in preventing venous thrombosis than unfractionated heparin. The latter is, ...

ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superior to Enoxaparin in the Prevention of Venous Thromboembolism Following Knee Replacement Surgery Phase ...

HealthDay News— For hospitalized, acutely ill medical patients, use of enoxaparin plus elastic stockings with graduated compressions, does not reduce the rate of death from any cause at 30 days, ...

In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit MAGELLAN study meets primary efficacy endpoints of ...

Oral rivaroxaban (Xarelto; Bayer/Janssen) is superior to subcutaneous enoxaparin in preventing venous thromboembolism (VTE) without increasing bleeding in patients undergoing nonmajor orthopedic ...

Two new major studies suggest that anticoagulant therapy with enoxaparin is an effective alternative to heparin therapy for patients with acute coronary syndromes (ACS), according to articles in the ...

A phase III study has shown that for patients undergoing knee replacement surgery, oral rivaroxaban is better than subcutaneous enoxaparin at preventing blood clots (venous thromboembolism/VTE). The ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...

Nonmajor orthopedic surgery of the lower limbs that results in transient reduced mobility places patients at risk for venous thromboembolism. Rivaroxaban may be noninferior to enoxaparin with regard ...